Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Japanese (NIKKEI) Pharma Industry Analysis

UpdatedJan 13, 2026
DataAggregated Company Financials
Companies40
  • 7D3.1%
  • 3M15.6%
  • 1Y18.0%
  • YTD1.7%

Over the last 7 days, the Pharma industry has risen 3.1%, driven by gains in Chugai Pharmaceutical and Astellas Pharma of 1.7% and 5.9%, respectively. This takes the industry's 12 month performance to a gain of 18%. Looking forward, earnings are forecast to grow by 11% annually.

Industry Valuation and Performance

Has the Japanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 13 Jan 2026JP¥47.9tJP¥16.9tJP¥1.9t16.6x25.2x2.8x
Thu, 11 Dec 2025JP¥45.5tJP¥16.9tJP¥1.9t15.5x23.9x2.7x
Sat, 08 Nov 2025JP¥41.8tJP¥16.9tJP¥1.9t14.9x21.7x2.5x
Mon, 06 Oct 2025JP¥41.2tJP¥16.8tJP¥1.8t15.6x22.6x2.5x
Wed, 03 Sep 2025JP¥40.6tJP¥16.8tJP¥1.8t15.8x22.2x2.4x
Fri, 01 Aug 2025JP¥41.4tJP¥16.8tJP¥1.8t17.4x22.9x2.5x
Sun, 29 Jun 2025JP¥40.2tJP¥16.8tJP¥1.8t15x22.8x2.4x
Tue, 27 May 2025JP¥40.4tJP¥16.8tJP¥1.8t14.3x22.9x2.4x
Thu, 24 Apr 2025JP¥40.5tJP¥16.5tJP¥1.5t15x26.9x2.5x
Sat, 22 Mar 2025JP¥40.7tJP¥16.5tJP¥1.5t16.1x27.1x2.5x
Mon, 17 Feb 2025JP¥40.1tJP¥16.5tJP¥1.5t16.1x26.7x2.4x
Wed, 15 Jan 2025JP¥41.0tJP¥16.1tJP¥1.4t15.8x29x2.6x
Fri, 13 Dec 2024JP¥42.3tJP¥16.1tJP¥1.4t15x29.9x2.6x
Sun, 10 Nov 2024JP¥45.0tJP¥16.1tJP¥1.4t15.7x31.7x2.8x
Tue, 08 Oct 2024JP¥44.4tJP¥15.5tJP¥1.2t16.1x36.9x2.9x
Thu, 05 Sep 2024JP¥46.8tJP¥15.5tJP¥1.2t17.6x38.9x3x
Sat, 03 Aug 2024JP¥43.9tJP¥15.5tJP¥1.2t17.2x36.9x2.8x
Mon, 01 Jul 2024JP¥42.4tJP¥15.0tJP¥1.1t18.2x38.7x2.8x
Wed, 29 May 2024JP¥40.7tJP¥15.0tJP¥1.1t16.5x37.2x2.7x
Fri, 26 Apr 2024JP¥39.0tJP¥14.7tJP¥1.2t18.5x32.3x2.7x
Sun, 24 Mar 2024JP¥43.3tJP¥15.1tJP¥1.2t20.1x35.6x2.9x
Tue, 20 Feb 2024JP¥42.2tJP¥15.1tJP¥1.2t20.7x34.8x2.8x
Thu, 18 Jan 2024JP¥41.5tJP¥15.2tJP¥1.4t20x30.2x2.7x
Sat, 16 Dec 2023JP¥38.8tJP¥15.2tJP¥1.4t19.1x28.2x2.6x
Mon, 13 Nov 2023JP¥38.7tJP¥15.1tJP¥1.4t22x28.2x2.6x
Wed, 11 Oct 2023JP¥39.8tJP¥14.9tJP¥1.4t23.6x27.8x2.7x
Fri, 08 Sep 2023JP¥40.4tJP¥14.9tJP¥1.4t23.3x28.3x2.7x
Sun, 06 Aug 2023JP¥38.6tJP¥14.9tJP¥1.4t21.1x27.1x2.6x
Tue, 04 Jul 2023JP¥40.3tJP¥14.6tJP¥1.5t21x27.5x2.8x
Thu, 01 Jun 2023JP¥39.3tJP¥14.6tJP¥1.5t19.5x26.9x2.7x
Sat, 29 Apr 2023JP¥38.7tJP¥14.3tJP¥1.5t18.2x26.4x2.7x
Mon, 27 Mar 2023JP¥36.6tJP¥14.3tJP¥1.5t16.6x24.9x2.6x
Wed, 22 Feb 2023JP¥37.1tJP¥14.3tJP¥1.5t17.2x25.3x2.6x
Fri, 20 Jan 2023JP¥36.6tJP¥13.7tJP¥1.4t19.2x27.1x2.7x
Price to Earnings Ratio

27.1x


Total Market Cap: JP¥36.6tTotal Earnings: JP¥1.4tTotal Revenue: JP¥13.7tTotal Market Cap vs Earnings and Revenue0%0%0%
Japanese Pharma Industry Price to Earnings3Y Average 28.8x202420252026
Current Industry PE
  • Investors are pessimistic on the Japanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 25.2x which is lower than its 3-year average PE of 28.8x.
  • The industry is trading close to its 3-year average PS ratio of 2.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 12% per year over the last three years.
  • Revenues for these companies have grown 7.4% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Japanese Healthcare industry?

JP Market-0.30%
Healthcare2.62%
Pharma3.07%
Pharma3.07%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
4503 Astellas PharmaJP¥2.26k6.2%
+JP¥236.4b		48.9%PE32.4x
4519 Chugai PharmaceuticalJP¥8.44k1.6%
+JP¥220.5b		24.1%PE35x
4578 Otsuka HoldingsJP¥9.20k3.9%
+JP¥180.1b		14.2%PE10.8x
4502 Takeda PharmaceuticalJP¥5.02k2.2%
+JP¥169.0b		21.8%PE239.7x
4568 Daiichi Sankyo CompanyJP¥3.54k2.6%
+JP¥164.7b		-14.8%PE23.4x

Latest News

4568
JP¥3,540.00
Daiichi Sankyo Company
7D
2.6%
1Y
-14.8%

4568: Expanding Oncology Pipeline And Legal Win Will Drive Future Upside

Analysts have kept their price target for Daiichi Sankyo Company steady at ¥6,300, citing only small adjustments to revenue growth, profit margin, and future P/E expectations, which supports maintaining the prior valuation view. What's in the News ENHERTU received multiple regulatory approvals and designations across the U.S., China, Canada and Europe for various HER2 positive, HER2 low and HER2 ultralow breast cancer settings, including first line metastatic treatment and early stage high risk neoadjuvant use, backed by phase 3 data from DESTINY-Breast06, DESTINY-Breast09 and DESTINY-Breast11 (Key Developments).
4519
JP¥8,437.00
Chugai Pharmaceutical
7D
1.6%
1Y
24.1%

4519: Renalys Acquisition And Merger Execution Risks Will Likely Limit Upside

Analysts have kept their price target for Chugai Pharmaceutical steady at ¥6,400, citing slightly more conservative revenue growth expectations, along with a small uplift in projected profit margins and a marginally higher future P/E multiple. What's in the News A board meeting is scheduled for October 24, 2025, to consider acquiring all shares and stock acquisition rights of Renalys Pharma, a domestic bioventure company, and to consider obtaining exclusive development and commercialization rights in Japan, South Korea, and Taiwan for sparsentan, which is being developed mainly for IgA nephropathy (Key Developments).
4506
JP¥2,825.50
Sumitomo Pharma
7D
12.0%
1Y
411.9%

Optimistic Investors Push Sumitomo Pharma Co., Ltd. (TSE:4506) Shares Up 26% But Growth Is Lacking

Jan 10
Optimistic Investors Push Sumitomo Pharma Co., Ltd. (TSE:4506) Shares Up 26% But Growth Is Lacking
4503
JP¥2,258.00
Astellas Pharma
7D
6.2%
1Y
48.9%
4507
JP¥2,895.50
Shionogi
7D
1.7%
1Y
28.8%

Shionogi & Co., Ltd.'s (TSE:4507) Shares May Have Run Too Fast Too Soon

Jan 10
Shionogi & Co., Ltd.'s (TSE:4507) Shares May Have Run Too Fast Too Soon
4578
JP¥9,195.00
Otsuka Holdings
7D
3.9%
1Y
14.2%

Should You Be Adding Otsuka Holdings (TSE:4578) To Your Watchlist Today?

Jan 09
Should You Be Adding Otsuka Holdings (TSE:4578) To Your Watchlist Today?
4502
JP¥5,020.00
Takeda Pharmaceutical
7D
2.2%
1Y
21.8%

4502: Stable Outlook Will Rely On Late Stage Pipeline And Dividends

Analysts kept their price target for Takeda Pharmaceutical steady at ¥4,946, reflecting largely unchanged assumptions around modest revenue growth, stable profit margins, and a future P/E of about 27x. What's in the News Takeda and Protagonist Therapeutics submitted a New Drug Application to the U.S. FDA for rusfertide for adults with polycythemia vera, following Phase 3 VERIFY and Phase 2 REVIVE data and multiple FDA designations including Breakthrough Therapy and Orphan Drug (Key Developments).
4530
JP¥6,369.00
Hisamitsu Pharmaceutical
7D
22.5%
1Y
38.1%
4523
JP¥4,718.00
Eisai
7D
-0.9%
1Y
10.2%

4523: Future Alzheimer Subcutaneous Rollout Will Not Support Current Share Price

Analysts have maintained their price target for Eisai at ¥3,600, citing updated assumptions for revenue growth, profit margins, and future P/E that continue to support the existing valuation framework. What's in the News Regulators in China accepted Eisai's Biologics License Application for a subcutaneous autoinjector formulation of Leqembi for early Alzheimer’s disease, with similar initiation dosing applications also submitted in the U.S. and Japan (Product related announcements) Eisai and partners reported clinical and modeling data at the CTAD conference suggesting long term lecanemab treatment was associated with delayed progression from mild cognitive impairment to more advanced Alzheimer’s stages, with subcutaneous dosing showing drug exposure comparable to intravenous administration (Product related announcements) Multiple filings were completed with the U.S. FDA for Leqembi Iqlik subcutaneous initiation dosing, following earlier approval for subcutaneous maintenance dosing.
4582
JP¥90.00
SymBio Pharmaceuticals
7D
-1.1%
1Y
-55.0%
4552
JP¥696.00
JCR Pharmaceuticals
7D
-0.6%
1Y
19.6%

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

Dec 26
JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00
4559
JP¥2,093.00
Zeria Pharmaceutical
7D
-0.6%
1Y
-5.9%
4888
JP¥238.00
Stella Pharma
7D
-18.5%
1Y
-53.2%

Does Stella Pharma (TSE:4888) Have A Healthy Balance Sheet?

Dec 22
Does Stella Pharma (TSE:4888) Have A Healthy Balance Sheet?
4890
JP¥335.00
Tsubota Laboratory
7D
-0.3%
1Y
-17.7%
4565
JP¥854.00
Nxera Pharma
7D
-1.7%
1Y
-12.0%
8095
JP¥485.00
Astena Holdings
7D
-1.6%
1Y
7.3%